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Abstract
Background: Studies have shown disparate results on the consequences of morphine use in ST-segment elevation
myocardial infarction (STEMI). No study has evaluated alternative treatments that could be at least non-inferior to
morphine without its potentially damaging consequences for myocardial function and platelet reactivity. The aim of
this study was to evaluate whether nitrous oxide/oxygen plus intravenous acetaminophen (NOO-A) is non-inferior
to morphine to control chest pain in STEMI patients.
Methods: This multicenter, open-label, cluster-randomized, controlled, non-inferiority study compared NOO-A with
morphine in 684 prehospital patients with ongoing suspected STEMI of < 12 h duration and a pain rating score ≥ 4.
The primary endpoint was the proportion of patients achieving pain relief (numeric rating score ≤ 3) after 30 min.
Secondary safety endpoints included serious adverse events and death at 30 days.
Results: The median baseline pain score was 7.0 in both groups. The primary endpoint occurred in 51.7% of the
NOO-A group and 73.6% of the morphine group (absolute risk difference − 21.7%; 95% confidence interval − 29.6 to
− 13.8). At 30 days, the rate of serious adverse events was 16.0 and 18.8% in the NOO-A and morphine groups
respectively (p = NS). The rate of death was 1.8% (NOO-A group) and 3.8% (morphine group) (p = NS).
Conclusion: Analgesia provided by NOO-A was inferior to morphine at 30 min in patients with acute STEMI in the
prehospital setting. Rates of serious adverse events did not differ between groups.
Trial registration: ClinicalTrials.gov: NCT02198378.
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Background
Pain can be particularly intense in ST-segment elevation
myocardial infarction (STEMI), leading to tachycardia,
increased stress, higher workload of the heart and dam-
aging effects on the myocardium [1]. Analgesia, adminis-
tered as soon as possible after symptom onset, is
therefore of paramount importance. Opioids (most com-
monly morphine) are recommended, [2] although their
efficacy and safety have not been fully evaluated in ran-
domized trials. Recently, the deleterious effect of mor-
phine on inhibition of platelet reactivity in STEMI
patients treated with P2Y12 inhibitors has been reported
[3–6]. Studies have reported that morphine is associated
with a delayed onset of action of oral antiplatelet drugs
due to vomiting or delayed gastric emptying, which re-
duce the absorption of these drugs [4].
Nitrous oxide/oxygen gas as an equimolar mixture is
widely used in emergency medicine and has been tested
in acute myocardial infarction [7]. It acts by activating
opioid neurons, leading to activation of the descending
noradrenergic inhibitory pathways that inhibit nocicep-
tion [8]. It has minor, rapidly reversible secondary effects
and no reported haemodynamic effects [9]. Few studies
in emergency medicine have compared Nitrous Oxid-
Oxygen to morphine with heterogenous results [10–12].
Acetaminophen is an effective and safe painkiller for
emergency department patients [13]. It has been success-
fully used in multimodal analgesia especially postoperative
analgesia [14]. Nitrous oxide/oxygen plus intravenous
acetaminophen (NOO-A) could therefore be a suitable al-
ternative to morphine. The association nitrous oxid-
oxygen plus intravenous acetaminophen was chosen for
reasons of delay in action. NOO has a 3–5min onset of
action and intravenous acetaminophen reaches its peak
concentration at the end of the 15-min infusion. There-
after, the duration of action of acetaminophen is 6 h while
the effect of nitrous oxid-oxygen stops 5min after inhal-
ation is stopped. Thus, Acetaminofen allowed continuing
the pain management once NOO was stopped.
The aim of the SCADOL II study was to assess in pa-
tients with acute STEMI managed in the prehospital set-
ting the non-inferiority in achieving analgesia at 30 min
of an equimolar mixture of NOO plus intravenous acet-
aminophen compared with intravenous morphine. The
secondary safety objectives were the rates of serious ad-
verse events and death at 30 days.
Methods
Study design
SCADOL II was a multicenter, open-label, cluster-
randomized, controlled, non-inferiority trial. Thirty-
eight mobile intensive care unit centers were random-
ized (1:1) to perform analgesia with NOO-A or intraven-
ous morphine. A computerized randomization process
was used to generate the random allocation sequence
and was carried out by the methodologist from the list
provided by participating centers. The details of the
SCADOL II investigators list is provided in Additional
file 1: Appendix 1.
The study has complied with the Declaration of
Helsinki, the locally appointed ethics committee has ap-
proved the research protocol and informed consent has
been obtained from the subjects (or their legally autho-
rized representative).
Selection of participants
Patients aged ≥18 years with suspected STEMI managed
by an emergency physician in a mobile intensive care
unit were eligible if they had symptom duration of < 12
h and a pain intensity score, assessed on a numeric rat-
ing scale, ≥4 (pain scale range 0–10).
Exclusion criteria were severe haemodynamic, respira-
tory, or neurological failure; heart failure; known allergy
or contraindication to morphine or nitrous oxide; mor-
phine or nitrous oxide administration within previous 4
h; incapacity to self-assess pain intensity on a numeric
rating scale; legal guardianship; pregnancy; or air ambu-
lance transport.
The reperfusion strategy (thrombolysis or angioplasty)
was chosen by the emergency physicians according to
guidelines [15]. To prevent delays in the performance of
revascularization, centers were randomly allocated be-
fore the start of the study, using a cluster design, to the
NOO-A or morphine group.
Study procedures
Analgesics were started by the emergency physician as
soon as possible after enrollment. In the control group,
morphine administration was titrated every 5min accord-
ing to pain intensity, assessed on a numeric rating scale: a
2mg bolus (or 1mg, for body weight < 60 kg) was given
for a numeric rating scale score 4–5; and a 3mg bolus (or
2mg, for body weight < 60 kg) for a score ≥ 6 [16]. In the
intervention group, nitrous oxide/oxygen was adminis-
tered according to the marketing authorization and under
supervision of the emergency physician, and was given for
≥30min (a minimum of 5min is necessary to obtain an
analgesic effect) [17]. Nitrous oxide/oxygen was combined
with 1 g intravenous acetaminophen in the framework
of a multimodal analgesia. After 15 min of use, if the
pain was still intense (numeric rating scale ≥6) the
emergency physician could change the analgesic strat-
egy and use morphine; such patients were considered
treatment failures. After 30 min and until arrival at
hospital, the emergency physician could change the
strategy of analgesia.
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Study endpoints
The primary endpoint was the proportion of patients
achieving pain relief with NOO-A (without any mor-
phine administration) or morphine, defined as a pain in-
tensity score on a numeric rating scale ≤3 [12, 18], 30
min after starting analgesia [19].
Secondary endpoints included the rate of pre-specified
adverse events in the two groups: respiratory depression,
defined as a respiratory rate < 10 cycles per minute, or a
respiratory score of ≥1 (see Additional file 1, definitions);
nausea; vomiting; sedation (measured by a Sedation
Scale score) of ≥2; dizziness; and pruritus.
Data on pain intensity, adverse events, and tolerance
(heart rate, non-invasive arterial pressure, pulse oxim-
etry) were collected at baseline, every 5 min up to 30
min after the start of analgesia, and at hospital arrival.
A 30-day safety analysis was done on incidence of ser-
ious adverse events and death occurring in the 30 days
post-treatment.
Study oversight
The executive and steering committee oversaw the con-
duct of the trial and the data analysis. The trial was
monitored by a clinical research assistant and the data
management was done by a data manager independent
of the steering committee. Statistical analysis were per-
formed blinded to treatment allocation. Finally, we com-
pleted the CONSORT checklist (Additional file 1:
Appendix 2).
Statistical analysis
We estimated that 684 patients and 38 mobile intensive
care unit centers (19 clusters) were needed to assess the
non-inferiority of NOO-A to achieve pain relief at 30
min, given an 80% expected proportion of pain achieve-
ment in the control group, a 10% non-inferiority margin,
a 2.5% one-sided alpha error rate, 80% power, and the
cluster design. Analysis were performed using SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA). A non-
inferiority margin was specified in the protocol as an ab-
solute difference of − 10% in proportion. The outcome
was deemed to be non-inferior if the lower limit of the
95% two-sided confidence interval (CI) was greater than
the non-inferiority margin. The main effect of NOO-A
versus morphine on the primary endpoint was assessed
using an unadjusted generalized estimating-equations
model with an exchangeable covariance matrix to ac-
count for the clustering of patients within centers. The
intracluster correlation coefficient was estimated by the
correlation parameter of the exchangeable covariance
matrix and by using linear mixed effect models with a
random center effect and the treatment as fixed effect,
as the intracluster correlation coefficient calculated ig-
noring potential treatment effects may be biased [20].
Additional analysis of the primary endpoint included an
adjustment for potential risk factors associated with an-
algesia (baseline pain score, age, sex, and thrombolysis).
Random imputations were performed on the basis of the
observed values to replace missing pain scores at base-
line. Finally, a pre-specified subgroup analysis was done
in patients with a confirmed STEMI diagnosis.
The per-protocol population (i.e. patients evaluable for
the primary endpoint without major protocol deviations)
was used for the primary endpoint analysis, as recom-
mended for a non-inferiority trial [21]. Secondary ana-
lysis were done in the intention-to-treat population (i.e.
all patients who entered the study, with the exception of
patients from prematurely closed centers); pain scores
missing at 30 min were imputed by means of the last-
observation-carried-forward method. If no pain score
was present after baseline, missing values were taken to
indicate failure (i.e. a pain score at 30 min of > 3).
In the safety analysis, the incidence of expected ad-
verse events (i.e. sedation, respiratory depression, vomit-
ing, nausea, pruritus, and dizziness), unexpected adverse
events, and adverse events leading to treatment discon-
tinuation in the 30min following initiation of analgesia
were computed. The proportions of patients with ≥1
expected adverse event in the 30 first minutes, and of
serious adverse events that occurred in the 30 days post-
treatment, were compared between groups using a
generalized estimating equation model, to account for
clustering.
Results
Study population
Between November 2014 and December 2016, 38 cen-
ters were randomized to the NOO-A or the morphine
strategy (19 in each arm). A total of 684 patients were
enrolled and composed the intention-to-treat population
(340 in the NOO-A group; 344 in the morphine group),
all of whom received the study treatment.
The per-protocol population comprised 644 patients
(315 in the NOO-A group; 329 in the morphine group)
(Fig. 1). The patient characteristics were well balanced
between groups (Table 1 and Additional file 1: Appendix
Table 1). Median pain intensity was 7.0 (interquartile Q1
to Q3: 5.0 to 8.0).
Efficacy
Patients in the morphine group were more likely to
achieve pain relief than those in the NOO-A group
(Fig. 2): the primary endpoint was obtained respectively
in 73.6% in the morphine group versus 51.7% of patients
in the NOO-A group. The absolute risk difference was
− 21.7% [95% Confidence Interval (CI) − 29.6 to − 13.8;
intracluster correlation coefficient 0.009975), which was
below the non-inferiority margin of − 10% defined in the
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protocol (Fig. 3). Analysis of the primary endpoint in the
intention-to-treat population showed the same effect
(absolute risk difference − 0.217; 95% CI − 0.297 to −
0.136; intracluster correlation coefficient 0.01518).
A similar observation (more likely to achieve pain re-
lief with morphine) was made in the subgroup of pa-
tients with a confirmed diagnosis of STEMI (NOO-A:
144 [50.3%] vs. morphine: 218 [71.7%]), with an absolute
risk difference of − 0.21 [95% CI − 0.29 to − 0.13).
Analysis of the primary endpoint in the per-protocol
population, adjusted for potential risk factors, showed
that better relief of chest pain was associated with mor-
phine treatment, lower pain score at baseline and in-
creasing age (Table 2).
Safety
The percentage of patients with a predefined adverse
event occurring within 30min of starting analgesia was
similar in the two study groups (13.2% with NOO-A and
10.2% with morphine).
(Table 3) (absolute risk difference of 0.032 [95% CI −
0.01 to 0.07]; P = 0.14). The most frequent expected
adverse event was vomiting (5.0% with NOO-A and
4.7% with morphine).
The percentage of patients with an unexpected (not
predefined) adverse event within 30 min of starting anal-
gesia was 6.2% with NOO-A and 3.5% with morphine,
the most frequent being ventricular fibrillation (1.2%
with NOO-A and 0.9% with morphine). The rate of ad-
verse events that led to treatment interruption within
the first 30 min was 7.1% with NOO-A and 1.2% with
morphine, the most frequent being vomiting (2.9% with
NOO-A and 0.3% with morphine).
The incidence of serious adverse event in the 30
days following inclusion was 18.8% with NOO-A and
16.0% with morphine (Table 3) (absolute risk differ-
ence of 0.033 [95% CI − 0.030 to 0.096]; P = 0.3). The
most frequent were ventricular tachycardia (3.8%),
ventricular fibrillation (1.9%), cardiogenic shock
(1.8%), and heart failure (1.1%). Most cases of ven-
tricular tachycardia (21 out of 26) were observed in
the NOO-A group.
Nineteen patients died during the 30 days following in-
clusion (Additional file 1: Appendix Table 2), 6 in the
NOO-A group (1.8%) and 13 in the morphine group
Fig. 1 Patient flow chart. Centres 10 and 20 performed the study in the morphine arm and then in the oxide/oxygen plus acetaminophen arm
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(3.8%). None of the deaths were judged to be directly re-
lated to the study treatment.
Limitations
The study has several limitations. Firstly, the low rate of
events in both groups made the study underpowered to
detect a clinically relevant difference in safety endpoints.
It is a common drawback encountered in STEMI studies
with prehospital recruitment that select lower risk pa-
tients. It does not by itself alter the conclusions of our
study. Secondly, even if the cluster randomization pro-
vided a pragmatic comparison of chest pain control
strategies in the prehospital setting, randomization takes
place before consent to participate and individual re-
cruitment. We tried to limit selection bias by a strict
monitoring of the study and the rigorous recording of
selection criteria. Of note, cluster randomization allowed
for the NOO-A treatment to be better included in
MICUs routine care. Influence of selection bias cannot
be completely ruled out. Thirdly, participants, physicians
and patients, were not blinded to the fact that they were
receiving morphine or NOO-A. It is therefore possible
that a measure reported by patients such as the numeric
rating score be influenced by physicians’ pre-existing
convictions. From a practical perspective – a double-
blind study would have necessitated the transport and
management of two gas cylinders in addition to the
standard equipment. The open design simplified prehos-
pital logistics and limited treatment delay.
Discussion
Contrary to our hypotheses, the main finding of our
study are that 1) NOO-A was actually inferior to intra-
venous morphine for the reduction of pain at 30 min in
patients with STEMI; 2) there were no more adverse
events in the morphine group. Controlling pain at the
acute phase of STEMI is challenging. Morphine has been
used for years and the issues of its efficacy and its safety
have been regularly raised [22, 23]. It has also been
linked to a delayed onset of action of oral antiplatelet
drugs [4, 5] Few alternatives to morphine have been
studied in STEMI, and analgesics that are appropriate
for the emergency setting (e.g. non-steroidal anti-
inflammatory drugs) are contraindicated [24–26].. The
choice of NOO-A combination was especially relevant
for use in STEMI. Nitrous oxide/oxygen has short onset
of action. It has few unwanted effects [9]. Acetamino-
phen is an effective and safe painkiller for patients in the
emergency department [13]. It was therefore intriguing
that the NOO-A combination provided such a relatively
low rate of pain relief with only half of the patients ex-
pressing a pain intensity less than 3 at 30 min. In con-
trast, in the morphine group, the proportion of patients
with adequate pain relief was high (73%) and consistent
Table 1 Characteristics of patients in the per-protocol
population
Nitrous oxide/oxygen
plus acetaminophen
(n = 315)
Morphine
(n = 329)
Age, years, mean ± SD 61.9 ± 13.7 62.1 ± 13.0
Male sex, n (%) 255 (81.0) 249 (75.7)
Body mass index,a kg/m2 n = 296 n = 307
Median (Q1; Q3) 25.8 (23.7; 28.1) 26.0 (23.9;
29.0)
≥30 kg/m2, n (%) 42 (14.2) 58 (18.9)
Smokers, n/N (%) 147/314 (46.8) 150/321 (46.7)
Diabetes,b n/N (%) 36/312 (11.5) 38/323 (11.8)
Hypertension, b n/N (%) 131/312 (42.0) 119/318 (37.4)
Hypercholesterolaemia, b
n/N (%)
82/305 (26.9) 95/315 (30.2)
Family history of cardiovascular
disease, n/N (%)
94/274 (34.3) 87/278 (31.3)
Previous coronary artery disease,
n/N (%)
55/311 (17.7) 56/324 (17.3)
Thrombolysis, n (%) 30 (9.5) 46 (14.0)
Decision of angioplasty, n (%) 296 (94.0) 308 (93.6)
Treatments at baseline, n (%)
Aspirin 313 (99.4) 323 (98.2)
Other antiplatelet (clopidogrel,
ticagrelor or prasugrel)
301 (95.6) 314 (95.4)
Clopidogrel 54 (17.1) 56 (17.0)
Ticagrelor 168 (53.3) 145 (44.1)
Prasugrel 81 (25.7) 116 (35.3)
Heparin 136 (43.2) 163 (49.5)
Low-molecular-weight
heparin
159 (50.5) 124 (37.7)
Bivalirudin 21 (6.7) 32 (9.7)
Anticoagulant (heparin, low-
molecular-weight heparin
or bivalirudin)
307 (97.5) 318 (96.7)
Beta-blocker 4 (1.3) 0
Glycoprotein IIb/IIIa inhibitor 6 (1.9) 9 (2.7)
Anxiolytic 2 (0.6) 10 (3.0)
Other treatment (administered
in mobile intensive care unit)
47 (14.9) 69 (21.0)
Delay between chest pain and
study treatment start, minutes
n = 314 n = 329
Median (Q1; Q3) 91.0 (65.0; 161.0) 100.0 (62.0;
167.0)
Pain score on numeric rating
scale at study treatment start
n = 314 n = 328
Median (Q1; Q3) 7.0 (5.0; 8.0) 7.0 (5.0; 8.0)
Q quartile, SD Standard deviation
aBody mass index is the weight in kilograms divided by the square of the
height in meters
bTreated
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with other studies [27, 28]. Intravenous acetaminophen
was administered at the recommended dose [16]. This
dose proved at least as potent than morphine in patients
with renal colitis [9]. It is possible that the NOO-A dos-
age was suboptimal in view of the high pain intensity of
patients with STEMI. Importantly, both treatments were
well tolerated. The rate of nausea or vomiting, events
that were specifically followed per protocol, was low and
did not differ between morphine and NOO-A groups.
Morphine is usually considered as responsible of vomit-
ing hence drug interactions, concerns for use in routine.
Since NOO-A is not supposed to increase the rate of
nausea and vomiting, it may be inferred that the role of
morphine in causing nausea and vomiting in STEMI has
been overstated. Other factors, especially parasympa-
thetic effect in STEMI with an inferior location and pain
Fig. 2 Percent of patients with pain score (numeric rating scale [NRS]) > 3. T, time in minutes
Fig. 3 Primary endpoint. CI, confidence interval
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intensity may play a more important role. It is clinically
relevant because vomiting and delayed gastric empty-
ing have been incriminated in the delayed onset of ac-
tion of oral antiplatelet drugs in patients treated with
morphine [4].
Overall, the rate of adverse events was not significantly
different between the NOO-A and the morphine groups.
The number of deaths was numerically higher in the
morphine group (3.8% vs 1.8% at 1 month). This statisti-
cally non-significant higher death rate in the morphine
group should not be an argument to renounce to this
potent analgesic in STEMI patients. However, this
observation adds to the uncertainties surrounding the
safety of morphine in ACS even if recent studies have
not shown an increase in mortality in patients treated
with morphine [5].
Conclusion
NOO-A was inferior to morphine analgesia at 30 min in
patients with acute STEMI in the prehospital setting.
Rates of adverse events were not significantly different
between the two treatment groups. Because morphine
appears to be such a potent agent of pain control in
STEMI, a randomised study specifically addressing its
safety is warranted.
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